ICU Medical, Inc. (ICUI) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-02-19
Business type: Treadmill
How it makes money
Profit depends on proprietary consumables and an installed base of Plum smart pumps that drive recurring sales of dedicated administration sets.
The business relies on a high-margin mix of infusion consumables, including the Clave needlefree connector line and Oncology closed system transfer devices.
Hardware sales of Plum precision pumps create an installed base that requires proprietary PlumSet dedicated IV sets, which enable the concurrent delivery of compatible medications through a single line.
What protects it: the moat
High switching costs arise from integrating Plum pumps with LifeShield software and hospital EHRs, supported by an eight-year top ranking from KLAS.
Its competitive moat is built on the interoperability of its Plum pumps with the LifeShield safety software and hospital electronic health records (EHR).
The Plum 360 has maintained the Best in KLAS award for eight years in a row, from 2018 through 2025, which reinforces brand loyalty within acute care hospitals.
What growth costs
It must spend several million dollars per automated assembly module and fund ongoing R&D to prevent infusion and vital care products from becoming obsolete.
Manufacturing requires high capital investment in specialized automated assembly machines and production molds, which have long lead times of nine months or more.
Ongoing innovation is necessary to maintain pricing power, as the medical device industry is characterized by rapid technological advances that put older products at risk of obsolescence.
What could damage it
In 2025, it incurred $33.6 million in tariffs, and a 15% rate on imports from Costa Rica threatens its primary manufacturing operations.
A causal chain of geopolitical friction led the U.S. to raise baseline reciprocal tariffs to 15% for Costa Rica, where the company maintains major manufacturing facilities.
Further risk exists under Section 232 investigations, which could classify medical consumables as national security threats and impose additional tariffs on the majority of its portfolio.
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.